Life Tech to 'Capitalize' on Existing Instrument Base to Expand MDx Business | GenomeWeb

Life Technologies this week broadly outlined its strategy for growing its molecular diagnostics business, which will include its next-generation sequencing platforms.

The company's new president of medical sciences, Ronnie Andrews, has been developing a "comprehensive strategy" to expand the firm's molecular diagnostics presence and to capitalize on its existing platforms and tools in the clinic, according to Greg Lucier, Life Tech's CEO and chairman.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.